Gavista - Sodium Alginate + Sodium Bicarbonate + Calcium Carbonate | VetSafeCare.Com

Brand

Gavista

Sodium Alginate + Sodium Bicarbonate + Calcium Carbonate — Ziska Pharmaceuticals Ltd.
(500mg + 267mg + 160mg) / 10 ml · (250mg + 133.5mg + 80mg) / chewable tablet

Alternatives

31

Routes

PO

Presentations

2

Generic profile Browse alternatives View combinations

Presentations

Oral Suspension · (500mg + 267mg + 160mg) / 10 ml

200 ml

৳250

Chewable Tablet · (250mg + 133.5mg + 80mg) / chewable tablet

1 chewable tablet

৳5

Dose rules

No structured dose rules are linked to this brand yet.

Dose reference

Human

For oral administration:Adult and children over 12 years:10-20 mL after meals and at bedtime, up to four times a day.Children 6 to 12 years: 5-10 mL after meals and at bedtime, up to four times a day.Children under 6 years: Not recommended.Elderly: No dosage modification is required for this age group.

Clinical notes

Applications:

N/A

Indication Notes:
This preparation is indicated in Gastric reflux, Heartburn, Flatulence associated with gastric reflux, Heartburn of pregnancy, All cases of epigastric and retrosternal distress where the underlying cause is gastric reflux.
Avoid In:

N/A

Contraindication Notes:
This product is contraindicated in patients with known or suspected hypersensitivity to the active ingredients or to any of the excipients.
The mode of action of the product is physical and does not depend on absorption into the systemic circulation. On ingestion, the product reacts rapidly with gastric acid to form a raft of Alginic acid gel having a near-neutral pH and which floats on the stomach contents quickly and effectively impeding gastro-esophageal reflux, for up to 4 hours. In severe cases, the raft itself may be refluxed into the esophagus in preference to the stomach contents and exert a demulcent effect.
A time-interval of 2 hours should be considered between this drug intake and the administration of other medicinal products, especially Tetracyclines, Digoxine, Fluoroquinolone, Iron salt, Ketoconazole, Neuroleptics, Thyroid Hormones, Penicillamine, beta-blockers (Atenolol, Metoprolol, Propranolol), Glucocorticoid, Chloroquine and Biphosphonates (diphosphonates) and Estramustine.
In addition to the desired effect of the drug, some side effects may appear such as: constipation, flatulence, stomach cramp or belching. In these cases consult a physician. If too big dose has been taken, there might appear a sensation of swelling. In this case, it is advisable to consult a physician.
In the event of over dosage symptomatic treatment should be given. The patient may notice abdominal distension.
Pregnancy: Clinical studies in more than 500 pregnant women, as well as a large amount of data from post-marketing experience, indicate no malformative nor feto/neonatal toxicity of the active ingredients. This drug can be used during pregnancy, if clinically needed.Breastfeeding: No effects of the active substances have been shown in breastfed newborns/infants of treated mothers. This drug can be used during breastfeeding.Fertility: Pre-clinical investigations have revealed Alginate has no negative effect on parental or offspring fertility or reproduction. Clinical data do not suggest that this drug has an effect on human fertility.
If symptoms do not improve after 7 days, the clinical situation should be reviewed. Each 10 mL dose has a Sodium content of 141 mg (6.2 mmoL). This should be taken into account when a highly restricted salt diet is recommended, e.g. in some cases of congestive cardiac failure and renal impairment. Each 10 mL dose contains 160 mg (1.6 mmoL) of Calcium Carbonate. Care needs to be taken in treating patients with hypercalcaemia, nephrocalcinosis and recurrent calcium containing renal calculi.